Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Ascl1 and NeuroD1-mediated astrocyte to neuron reprogramming in an ischemic stroke model
EF 2022-23
Résumé
Stroke is a leading cause of death and disabilities worldwide. A promising approach to treat stroke is astrocyte to neuron (AtN) reprogramming to promote neural repair. Reactive astrocytes are a promising target for cell conversion due to their abundance, contribution to the glial border, and role in neurotoxicity following stroke. Past and ongoing work has shown that adeno-associated virus (AAV) delivery of the neurogenic transcription factors (TFs), Ascl1 and NeuroD1 in vivo to the stroke injured brain, leads to cortical neuron regeneration and improved functional outcomes. However, it is unknown which TF leads to more efficient AtN conversion. We propose to compare Ascl1 and NeuroD1 using a strategy to track virally transduced astrocytes, without the use of AAV-Cre constructs to deliver TFs, which has led to controversy in the literature with studies reporting off-target effects. We will use inducible transgenic mice that allow us to label endogenous astrocytes prior to the injury so we can follow them after the intervention. Mice will receive a stroke in the sensorimotor cortex followed by injection of AAV expressing the neurogenic TFs which will be designed for expression in reactive astrocytes. We will quantify AtN conversion and assess functional outcomes for up to 6 months, as measures of success. We hypothesize that Ascl1 will result in more efficient AtN conversion and more rapid motor recovery compared to NeuroD1 in a model of subacute stroke since Ascl1 is critical in development for neuronal fate decisions. These studies will generate important data to assess whether AtN conversion is a therapeutic strategy to promote repair of the stroke injured brain.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486014
Name
Li Fei
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Ascl1 and NeuroD1-mediated astrocyte to neuron reprogramming in an ischemic stroke model
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aav; Adult Neurogenesis; Ascl1; Astrocyte Lineage Tracing; Astrocytes; Gene Therapy; In Vivo Reprogramming; Ischemic Stroke; Neurod1; Neurons
Abstract
Stroke is a leading cause of death and disabilities worldwide. A promising approach to treat stroke is astrocyte to neuron (AtN) reprogramming to promote neural repair. Reactive astrocytes are a promising target for cell conversion due to their abundance, contribution to the glial border, and role in neurotoxicity following stroke. Past and ongoing work has shown that adeno-associated virus (AAV) delivery of the neurogenic transcription factors (TFs), Ascl1 and NeuroD1 in vivo to the stroke injured brain, leads to cortical neuron regeneration and improved functional outcomes. However, it is unknown which TF leads to more efficient AtN conversion. We propose to compare Ascl1 and NeuroD1 using a strategy to track virally transduced astrocytes, without the use of AAV-Cre constructs to deliver TFs, which has led to controversy in the literature with studies reporting off-target effects. We will use inducible transgenic mice that allow us to label endogenous astrocytes prior to the injury so we can follow them after the intervention. Mice will receive a stroke in the sensorimotor cortex followed by injection of AAV expressing the neurogenic TFs which will be designed for expression in reactive astrocytes. We will quantify AtN conversion and assess functional outcomes for up to 6 months, as measures of success. We hypothesize that Ascl1 will result in more efficient AtN conversion and more rapid motor recovery compared to NeuroD1 in a model of subacute stroke since Ascl1 is critical in development for neuronal fate decisions. These studies will generate important data to assess whether AtN conversion is a therapeutic strategy to promote repair of the stroke injured brain.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Fei
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~